MedTrace Logo

Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males

NCT00814931 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2009-01-13

No results posted yet for this study

Summary

The purpose of this study is to assess the effects of CXB722 on neuroendocrine stress response and subjective reports related to mood and stress during and after experimentally induced stress among healthy young males.

Conditions

Interventions

DRUG

CXB722

900 mg CXB722 oral liquid suspension twice a day for 8 days

DRUG

Placebo

matching oral liquid suspension placebo twice a day for 8 days

Sponsors & Collaborators

  • CeNeRx BioPharma Inc.

    lead INDUSTRY

Principal Investigators

  • Carlos Santana, MD · USF Physicians Group, Associate Professor, Director of Adult Outpatient Services, Department of Psychiatry and Behavioral Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
34 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00814931 on ClinicalTrials.gov